Clinical Trial

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2023 (before its estimated December 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-07-03.
Trial Details
NCT Number NCT05933967
Lead Sponsor Shandong Cancer Hospital and Institute
Collaborators: The First Affiliated Hospital of Nanchang University
Conditions The First Affiliated Hospital of Nanchang University
Enrollment 31 participants
Start Date 2023-06-01
Primary Completion 2024-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2023-08-15